DUBLIN – Eighteen months after terminating its interest in Adocia SA's Biochaperone technology, Eli Lilly and Co. is paying $50 million up front to get it back, and it could hand over another $520 million in development, regulatory and commercial milestones linked to the progress of Adocia's ultra-fast-acting insulin formulation, Biochaperone Lispro.